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prevention. RESULTS: The expected number of avoided AD cases by selecting PHF-W 
over CMF was 2,787 cases in a birth cohort of 38,661 at risk infants. The base-case 
analyses generated expected ICERs of c1921, -c1102 (savings) and c785 from the 
MOH, family and SOC perspectives, respectively. Cost drivers were formula from the 
MOH perspectives and time loss from the family perspective, with formula and to a 
lesser extent time loss for the SOC perspective. PHF-W yielded approximately c10.7 
million savings against EHF in the secondary analysis. One-way and probabilistic 
sensitivity analyses conﬁ rmed the robustness of the model. CONCLUSIONS: Under 
a range of assumptions, this analysis has established the cost-effectiveness of PHF-W 
in the prevention of AD among Spanish infants.
PSS19
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OBJECTIVES: Bevacizumab (Avastin) is a promising and low cost treatment of age-
related macular degeneration. Effectiveness and cost-effectiveness might be related to 
the frequency of injections of bevacizumab in the treatment. The standard frequency 
is 4 weeks, while it is uncertain whether lower frequencies lead to different cost and 
effects. METHODS: 170 patients were randomized to 3 treatment frequencies; 4, 6, 
and 8 week intervals between injections. Follow up was 1 year. Vision was measured 
with the Snellen chart, which health states have been valued for QALY analysis. We 
developed a 6 states Markov model with a 12 weeks cycle and a 6-year time-horizon. 
The model included one death state, and ﬁ ve states deﬁ ned by visual acuity(VA) in 
the better seeing eye: VA >20/40, ≤20/40 to >20/80, ≤20/80 to >20/200, ≤20/200 to 
>20/400 and ≤20/400. RESULTS: At time of the (interim) analyses, 72 patients had 
completed the full follow up. The ‘6 weeks’ frequency compared with ‘4 weeks’ shows 
a negative ICER of c6.406, with c1,024 less costs and 0.16 more QALY’s. The ‘8 
weeks’ frequency compared to the 4 weeks frequency shows also a negative ICER of 
c28,032, with c1.543 less costs and 0,06 more QALY’s. When looking at 6 and 8 
weeks, the ‘8 weeks’ has lower costs but is also less effective, with an ICER of c4.946. 
Most uncertainty related to utilities and transition probabilities, while cost contributes 
relatively less to the uncertainty of the outcomes. CONCLUSIONS: Compared with 
4 weeks frequency, the 6 and 8 weeks frequency were dominant, whereas the 8 weeks 
frequency has an ICER in the south west quadrant.
PSS20
COST-UTILITY ANALYSIS OF A PRN (AS NEEDED) TREATMENT 
SCHEDULE WITH RANIBIZUMAB (LUCENTIS®) IN WET AMD BASED 
ON CLINICAL EVIDENCE
Moeremans K1, Gerlier L1, Mitchell P2, Gallagher M3, Vincze G3
1IMS Health Consulting, Brussels, Belgium; 2University of Sidney, Westmead, NSW, Australia; 
3Novartis Pharma AG, Basel, Switzerland
OBJECTIVES: To assess whether evidence-based cost-utility of PRN-dosing with 
ranibizumab (Lucentis®, RBZ-PRN) in age-related macular degeneration (AMD) is 
comparable to RBZ-PRN cost-utility estimated previously based on clinical data from 
monthly and quarterly regimens. METHODS: A 10-year MS-Excel Markov model 
with 5 visual acuity (VA) levels and 1 death state predicts VA in patients treated with 
RBZ-PRN, RBZ quarterly (RBZ-Q), RBZ monthly (RBZ-M), Visudyne® photody-
namic therapy (PDT) or best supportive care (BSC). Transition probabilities, adverse 
events and treatment frequencies were provided by newly available PRN-trials 
(SUSTAIN, MONT BLANC) + available trials covering other comparators (ANCHOR, 
MARINA, PIER, EXCITE, TAP). Comparability of populations and treatment effects 
(linear regressions) determined trial data pooling. Final analyses included pooled data 
sets (RBZ-PRN and RBZ-Q) or multiple single-trial data sets (other comparators). 
Secondary analysis included indirect comparison versus pegaptanib sodium (PGB). 
Two-year treatment duration was followed by BSC. Costs (2009, UK health care 
payer, 3.5% discount) were obtained from literature and expert opinion; utilities 
(3.5% discount) from a time-trade-off study. One-way and probabilistic sensitivity 
analyses (SA) covered variability in efﬁ cacy, costs, treatment frequency and utilities. 
RESULTS: Due to lower than predicted injection frequency, clinical trial-based cost-
utility of RBZ-PRN was better than predicted cost-utility. Evidence-based cost-utility 
ranged from £4,414/QALY to £20,489/QALY versus BSC and from dominance to 
£2,383/QALY versus PDT. RBZ-PRN was dominant versus RBZ-Q and versus PGB 
(secondary indirect analysis). RBZ-M was slightly more effective but not cost-effective 
versus RBZ-PRN. The result was most sensitive to time horizon (2–10 y), cost of 
blindness and treatment duration (1–3 y) but conclusions remained throughout 1-way 
SA. Assuming a threshold of £30,000/QALY, the probability that RBZ-PRN is cost-
effective ranged from 68% to 97% versus different comparators. CONCLUSIONS: 
RBZ-PRN using the SUSTAIN and MONT-BLANC re-treatment criteria is cost-
effective compared to other therapies for wet-AMD and represents the most cost-
effective use of RBZ.
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OBJECTIVES: The objective of this study was to determine the cost-effectiveness of 
tacrolimus ointment used twice weekly as a maintenance treatment regimen compared 
to a standard treatment regimen using tacrolimus twice daily in both adults and 
children with moderate to severe atopic dermatitis (AD) in Norway and Finland. 
METHODS: A decision analytic approach was used to compare costs and outcomes 
of two alternative management strategies for AD over a 12 month treatment period 
for the UK, which was adapted for Norway and Finland. Efﬁ cacy data were used from 
two randomised controlled trials where maintenance use of tacrolimus ointment 
(0.1% in adults and 0.03% in children applied twice weekly) was applied to previously 
affected areas compared to standard use (twice daily application) to treat disease 
exacerbations. Utility data were derived from a published source and cost data were 
taken from public list prices and tariffs in the two countries, Norway and Finland to 
generate cost/QALY. Sensitivity analyses were performed to test the degree of uncer-
tainty around the results. RESULTS: The twice weekly maintenance use of tacrolimus 
ointment resulted in fewer days in disease ﬂ are and improved quality of life versus 
standard treatment with tacrolimus ointment in both adults and children with moder-
ate to severe AD. The twice weekly regimen was cost-saving compared with the 
standard regimen in both Norway and Finland. Sensitivity analyses demonstrated that 
results were largely insensitive to change. CONCLUSIONS: Twice weekly mainte-
nance treatment of moderate and severe AD in both adults and children using tacro-
limus ointment improves health outcomes at a lower cost when compared with the 
reactive treatment strategy using tacrolimus ointment.
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Indirect costs are not only generated by sick people themselves, but often occur due 
to sick children needing informal care by parents or other informal care givers. Infor-
mal care givers are relatives or friends, not being paid for their services and thereby 
experiencing work, leisure time and productivity loss. Indirect costs induced by infor-
mal care givers are rarely included in CEA, although being part of societal cost. 
OBJECTIVES: This study quantiﬁ ed the indirect costs of an informal care giver caused 
by a sick child suffering from an episode of acute otitis media (AOM) in Germany. 
METHODS: Using a German access panel questionnaires were sent out to households 
with children <5years. The following indirect costs referring to the most recent AOM 
episode of any child were covered: hours of work absence and related costs for 
mothers, fathers and grandparents; loss of leisure time; productivity loss caused by 
solicitousness; work loss compensation by colleagues. RESULTS: A total of 68.3% of 
all parents experienced 7–29 hours of work loss (59.3/9.3% mothers/fathers) per 
episode, grandparents 14 hours (2%). While 40% of parents experienced paid and 
28% unpaid work loss, grandparents being retired caused only unpaid productivity 
losses. Leisure time loss was experienced by all informal caregivers and an average 
was calculated across the total population accounting for c47.39. Indirect costs per 
AOM episode across the total population were in average c411.40 (Sum of: c152.51 
paid, c161.89 unpaid work loss, c209.07 productivity, c47.39 leisure time loss; 
Subtraction of: c45.72 paid, c113.74 unpaid work compensation by a colleague). 
CONCLUSIONS: Indirect costs are mainly included in health economic (HE) analyses 
as paid work loss. For Germany paid work loss only accounted for 38% of total 
indirect costs referring to an AOM episode. Further detailed studies are needed to 
better understand the inﬂ uence of different indirect cost categories across disease areas. 
SENSORY SYSTEMS DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: To measure the inﬂ uence of introducing guidelines to doctors and 
educational leaﬂ ets to patients on reducing the level of prescribed antibiotics. To 
investigate the effect of factors such as socio-demographic characteristics, signs, symp-
toms and patient self management. METHODS: Research was conducted in two busy 
clinics, one in Dubai and one in Sharjah. a set of guidelines for the treatment of sore 
throat were extracted from the SIGN guidelines (Appendix 3). The set of guidelines 
was explained to the General Practitioners individually. The guidelines were accom-
panied by a covering paper which explained why and where the guidelines were 
produced. The researcher was based in the nursing room and approached patients 
suffering from a sore throat. These patients were given the educational leaﬂ et and a 
brief explanation of what the leaﬂ et included. The length of explanation depended on 
whether the patient could read or not. They were then asked a set of questions prior 
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to their visit to General Practitioner. Study population I: Before the implementation 
of guidelines and the educational leaﬂ et. Study population II: After the implementation 
of guidelines and the educational leaﬂ et. Cross-sectional analysis and descriptive 
analyses was performed using the Statistical Package for Social Sciences (SPSS). 
RESULTS: The total number of antibiotic prescriptions for patients suffering from 
U.R.T.I. including sore throat was signiﬁ cantly reduced in the intervention group 
(67% reduction). CONCLUSIONS: A multi-dimensional interventional approach for 
reducing antibiotic prescription in U.A.E. clinics resulted in a signiﬁ cant positive 
outcome. The signiﬁ cant reduction in antibiotic prescriptions indicates the willingness 
of physicians to follow guidelines and the willingness of patients to respond to edu-
cational information.
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OBJECTIVES: To estimate the impact of ocular hypertension (OHT)/primary open-
angle glaucoma (POAG) on health status and quality-of-life. METHODS: Classiﬁ ca-
tion of disease state followed European Glaucoma Society guidelines. Health status 
was based upon the Health Utility Index Mark 3 (HUI3) The National Eye Institute 
25-Item Visual Function Questionnaire (NEI-VFQ-25) was self-administered. Utility 
scores were compared to a normal population matched by age and gender. Differences 
in health impact and quality-of-life between the different disease states were assessed. 
RESULTS: 154 patients were enrolled (27 OHT, 43 early, 35 moderate, 49 advanced 
POAG) from 15 centers in Germany, 137 were diagnosed 35 years ago. Average age 
was 67 ± 11 and 57% were female. 23% of patients had cardiovascular co-morbidity, 
45% history of cataract, 45% hypertension, 18% diabetes, and 10% hypotension. 
Differences in baseline characteristics were seen for age (60, 63, 69, 72 years), history 
of cataract (24%, 25%, 54%, 62%), employment status (43%, 24%), and hypoten-
sion (14%, 0%, 14%, 15%). The HUI3 score for OHT, early, moderate and advanced 
POAG was 0.87 ± 0.09, 0.85 ± 0.15, 0.75 ± 0.23 and 0.58 ± 0.32, respectively. There 
was no difference in the health utility score for patients with OHT, early POAG and 
the normal population. Patients with moderate and advanced POAG were lower by 
0.06 ± 0.24 and 0.19 ± 0.28, signiﬁ cantly different from OHT and early POAG (P < 
0.01). The NEI-VFQ-25 for OHT and early POAG gave ocular symptoms and mental 
health the lowest scores. For moderate POAG the lowest scores were for driving, 
ocular symptoms, mental health, role limitation and peripheral vision. For advanced 
POAG, all domains, except color vision, were affected. CONCLUSIONS: Disease 
progression in glaucoma affects not only vision, but also quality-of-life. Whereas OHT 
and early POAG have little effect on quality-of-life, moderate and advanced POAG 
do. These ﬁ ndings can improve doctor-patient relationships, addressing quality-of-life 
issues for different glaucoma disease states.
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OBJECTIVES: The aim of the current study was to develop an algorithm to map the 
symptom domain of the Impact of Dry Eye on Everyday Life (IDEEL) questionnaire 
to a preference based utility index. METHODS: Data from an IDEEL psychometric 
validation study including 210 participants (130 dry eye patients, 32 Sjogren’s patients 
and 48 controls) were used to estimate the algorithm. Participants completed the 
IDEEL, EQ-5D and SF-36 at 2 time points; the ﬁ rst time point was used to estimate 
the algorithm and the second to validate the algorithm. The mapping work was 
preceded by determining bivariate correlations between the IDEEL items and each 
utility index (EQ-5D and SF-6D), and then examining the sensitivity of each index to 
variability in dry eye severity. Initial items were selected based on levels of missing 
data, ﬂ oor and ceiling effects and correlations with the utility index. Items were then 
included in an OLS regression model with age and gender interaction terms. Following 
the item analysis the same procedures were applied to a domain level analysis. 
RESULTS: Based on the criteria outlined above, the SF-6D was selected as the utility 
index for the mapping algorithm. The ﬁ nal OLS regression model contained 2 IDEEL 
symptoms items and age, and explained 28% of the variance in SF-6D utility values; 
root mean squared error (RMSE) = 0.105. As the SF-6D data included few bounded 
or censored estimates Tobit and CLAD models were not estimated. The validation 
data set demonstrated a signiﬁ cant correlation between the predicted and observed 
SF-6D utility values (r = 0.53, p < 0.001). CONCLUSIONS: This algorithm forms a 
good basis to estimate utility values from the IDEEL for inclusion in cost-effectiveness 
analysis.
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OBJECTIVES: To identify and review published utility estimates in atopic dermatitis 
(AD), and to catalogue the methods of utility assessment, patient populations studied, 
and economic evaluations incorporating the utility estimates. METHODS: A system-
atic search and review of the published literature, including health technology assess-
ments, in AD was performed. Utility search terms were those recommended by NICE 
in the UK Publications were limited to English language only, from 1999 through 
2010. RESULTS: Fourteen studies presenting 15 different sets of utility data in AD 
(one study used two separate methods to generate estimates) were identiﬁ ed. These 
14 studies are summarized in 11 separate publications (one health technology assess-
ment describes three otherwise unpublished utility studies). All studies but one present 
utility estimates (vs changes in utility). Two studies present a single utility estimate 
for AD. One study presents utility estimates for controlled vs. uncontrolled AD. All 
other studies present utility estimates by AD severity (e.g., clear, mild, moderate, 
severe), although only two studies link AD severity directly to IGA scores. Two studies 
present utility estimates for children. AD utilities have been collected or applied in 
economic evaluations in Canada, Germany, Sweden, the UK, and the US. Utilities in 
AD have been collected directly using SG, TTO, VAS (with the VAS results being 
converted into utilities for use in economic evaluations using an algorithm that reﬂ ects 
attitudes towards risk), and using the EQ5D. Three studies have generated utility 
estimates based on applying two separate published algorithms to SF-12 or SF6D data. 
Five sets of utility data have been used in economic evaluations. CONCLUSIONS: 
There are several published studies presenting utility estimates in AD; however, they 
vary greatly in terms of methods employed. Economic evaluations in AD, the results 
of which are sensitive to uncertainty in utility inputs, have relied on various 
estimates.
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OBJECTIVES: The assessment of quality of life (QoL) in dermatology is becoming 
increasingly popular as demonstrated by the creation and development of numerous 
questionnaires for the principal diseases of the skin. Paradoxically, although cosmetic 
dermatology is rapidly developing, there is no questionnaire to assess the impact of 
these products on the QoL of the women that use them. There was therefore a need 
for the creation of the Cosmeti QoL. METHODS: The questionnaire was developed 
using rigorous methodology in accordance with international standards in terms of 
quality of life. a literary review and face-to-face interviews were conducted to identify 
the concepts that preoccupied women over 25 years of age. Twenty-two items were 
identiﬁ ed after the ﬁ rst transcription; this was reduced to 12 items after an initial 
analysis making it easier to use. a representative population of 1002 French women 
aged 25 years and over, was put together by the CSA Santé institute using the quota 
method. They were given the Cosmeti QoL; the lower the score the better the Qol. 
RESULTS: The questionnaire is easy to use, good comprehension of the questions was 
observed. The Cosmeti QoL score is correlated to age. An improved QoL is seen in 
women who frequently use a moisturizing cream (13.7 vs. 14.23, P < 0.001). Sensitive 
skin resulted in poorer QoL (14.77 vs. 13.34 P < 0.001), the frequency of episodes 
of sunburn during childhood also reduced the QoL (14.96 vs. 13.86 P < 0.001). In 
the population over 65 years of age, the QoL was superior in women who claimed to 
use cosmetic, anti-wrinkle, or moisturizing products on a regular basis. CONCLU-
SIONS: The Cosmeti QoL scale, which is essentially based on the women’s point of 
view, is a valid, pertinent, and well accepted tool enabling the assessment of quality 
of life perceived through the skin.
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OBJECTIVES: No consensus on deﬁ nition of plaque psoriasis severity currently exists. 
Although standard measures of psoriasis severity are commonly used in clinical prac-
tice, they are not consistent and rarely based on patient assessment. The objective was 
to develop an instrument assessing patient and physician perceptions of psoriasis 
severity and treatment effect. METHODS: Semi-directive exploratory interviews were 
conducted with 20 patients with mild to severe plaque psoriasis, and with 20 derma-
tologists. Interviews’ transcripts were analyzed to extract and organise into models 
the criteria used by patients and physicians to evaluate psoriasis severity and treatment 
beneﬁ t. Items were generated using patient words for each concept considered relevant 
by both patients and dermatologists. The instrument was developed in parallel for 
patients and for physicians, tested for relevance and comprehension on 5 patients and 
5 physicians, and revised accordingly. The new version was tested on 5 new patients 
and 5 new physicians and revised to create a pilot version. a dermatologist advisory 
board was involved at each step of the instrument development. RESULTS: The test 
instrument consisted in 31 items including area involvement, lesion location, signs and 
symptoms (frequency, duration of lesions, joint involvement), treatment history, 
quality of life impact, rapidity and duration of treatment beneﬁ t, and patient satisfac-
tion. The instrument was globally well-accepted by patients and physicians; few 
modiﬁ cations were made. a 32-item pilot version resulted from the comprehension 
